{{Rsnum
|rsid=10519613
|Gene=IL15
|Chromosome=4
|position=141732931
|Orientation=plus
|GMAF=0.202
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
|Gene_s=IL15
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;C)
| geno3=(C;C)
| CEU | 0.9 | 18.6 | 80.5
| HCB | 17.5 | 46.0 | 36.5
| JPT | 16.1 | 48.2 | 35.7
| YRI | 0.0 | 2.0 | 98.0
| ASW | 0.0 | 17.5 | 82.5
| CHB | 17.5 | 46.0 | 36.5
| CHD | 21.1 | 53.2 | 25.7
| GIH | 3.0 | 22.8 | 74.3
| LWK | 0.0 | 1.9 | 98.1
| MEX | 13.8 | 48.3 | 37.9
| MKK | 0.0 | 8.3 | 91.7
| TSI | 1.0 | 18.6 | 80.4
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs10519613
|Name_s=
|Gene_s=IL15
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal residual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: A, MAF= 0.13, combined P value= 1.31E-04.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470195
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs10519613
|overall_frequency_n=18
|overall_frequency_d=126
|overall_frequency=0.142857
|n_genomes=14
|n_genomes_annotated=0
|n_haplomes=15
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}